Summary: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cAC10) conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage. Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
Description: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cAC10) conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage. Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
